AbCellera Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 586

Employees

  • Stock Symbol
  • ABCL

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $3.85
  • (As of Friday Closing)

AbCellera General Information

Description

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 2215 Yukon Street
  • Vancouver, British Columbia V5Y 0A1
  • Canada
+1 (604) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AbCellera Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.85 $3.85 $3.58 - $8.05 $1.13B 294M 1.35M -$0.52

AbCellera Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 643,098 951,789 2,106,099 3,303,197
Revenue 35,788 38,025 485,424 375,203
EBITDA (180,978) (185,382) 256,122 233,069
Net Income (146,898) (146,398) 158,519 153,464
Total Assets 1,463,096 1,488,094 1,540,907 1,318,569
Total Debt 73,610 77,380 82,258 40,065
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AbCellera Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AbCellera‘s full profile, request access.

Request a free trial

AbCellera Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barr
Biotechnology
Vancouver, Canada
586 As of 2023
00000
00000000 00000

000000

mmodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000000
Copenhagen, Denmark
0000 As of 0000
00.000
00.000 0000-00-00
000000000 00.000

000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000 000000000
Cambridge, MA
00 As of 0000
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AbCellera Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genmab Formerly VC-backed Copenhagen, Denmark 0000 00.000 000000000 00.000
HiFiBiO Therapeutics Venture Capital-Backed Cambridge, MA 00 00000 000000000000 00000
Precigen Formerly VC-backed Germantown, MD 000 00000 000000000 00000
Azitra Formerly VC-backed Branford, CT 00 000.00 00000000 000.00
Sphere Fluidics Venture Capital-Backed Cambridge, United Kingdom 00 000.00 0000000000 0 000.00
You’re viewing 5 of 51 competitors. Get the full list »

AbCellera Patents

AbCellera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230295310-A1 Cd3 t-cell engagers and methods of use Pending 20-Mar-2022 00000000000
AU-2022357559-A1 Transgenic rodents for cell line identification and enrichment Pending 01-Oct-2021
CA-3232212-A1 Transgenic rodents for cell line identification and enrichment Pending 01-Oct-2021 0000000000
AU-2022320541-A1 Antibody competition model using affinities of hidden variables Pending 08-Jul-2021 000000000
CA-3225236-A1 Antibody competition model using affinities of hidden variables Pending 08-Jul-2021 G16B15/30
To view AbCellera’s complete patent history, request access »

AbCellera Executive Team (16)

Name Title Board Seat Contact Info
Carl Hansen Ph.D Chief Executive Officer & Founder
Andrew Booth Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Veronique Lecault Founder & Chief Operating Officer, Operations
Tryn Stimart Secretary, Administration & Chief Compliance Officer, Legal
Graham Craig Director, Corporate Development
You’re viewing 5 of 16 executive team members. Get the full list »

AbCellera Board Members (7)

Name Representing Role Since
Andrew Lo Ph.D AbCellera Board Member 000 0000
John Montalbano Self Board Member 000 0000
Michael Hayden Ph.D Self Board Member 000 0000
Peter Thiel JD Self Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

AbCellera Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AbCellera Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AbCellera‘s full profile, request access.

Request a free trial

AbCellera Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Empirico 20-Mar-2023 00000 0000 000.00 Drug Discovery
Abdera Therapeutics 01-May-2022 00000 0000 0000 Drug Discovery
TetraGenetics 10-Sep-2021 0000000000 0000 Drug Discovery 000000 00
Abdera Therapeutics 25-Jan-2021 0000 00000 00.000 Drug Discovery
Trianni 18-Nov-2020 Merger/Acquisition 0000 Drug Discovery 0000 0000
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

AbCellera Subsidiaries (1)

Company Name Industry Location Founded
TetraGenetics Drug Discovery Arlington, MA 0000
To view AbCellera’s complete subsidiaries history, request access »

AbCellera ESG

Risk Overview

Risk Rating

Updated November, 22, 2023

29.73 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,421

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 928

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 407

Rank

00.00

Percentile

To view AbCellera’s complete esg history, request access »

AbCellera FAQs

  • When was AbCellera founded?

    AbCellera was founded in 2012.

  • Who is the founder of AbCellera?

    Carl Hansen Ph.D, Veronique Lecault, Kathleen Lisaingo Ph.D, Daniel Da Costa, and Oleh Petriv Ph.D are the founders of AbCellera.

  • Who is the CEO of AbCellera?

    Carl Hansen Ph.D is the CEO of AbCellera.

  • Where is AbCellera headquartered?

    AbCellera is headquartered in Vancouver, Canada.

  • What is the size of AbCellera?

    AbCellera has 586 total employees.

  • What industry is AbCellera in?

    AbCellera’s primary industry is Biotechnology.

  • Is AbCellera a private or public company?

    AbCellera is a Public company.

  • What is AbCellera’s stock symbol?

    The ticker symbol for AbCellera is ABCL.

  • What is the current stock price of AbCellera?

    As of 24-May-2024 the stock price of AbCellera is $3.85.

  • What is the current market cap of AbCellera?

    The current market capitalization of AbCellera is $1.13B.

  • What is AbCellera’s current revenue?

    The trailing twelve month revenue for AbCellera is $35.8M.

  • Who are AbCellera’s competitors?

    Genmab, HiFiBiO Therapeutics, Precigen, Azitra, and Sphere Fluidics are some of the 51 competitors of AbCellera.

  • What is AbCellera’s annual earnings per share (EPS)?

    AbCellera’s EPS for 12 months was -$0.52.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »